User login
Key clinical point: Alpha-lipoic acid (ALA) supplementation may serve as a potential adjunct treatment option for migraine.
Main finding: ALA supplementation vs. placebo over 3 months caused a significant decrease in baseline mean headache severity (−3.59 vs. −0.70; P < .001), frequency of attacks/month (−2.55 vs. −0.40; P = .001), headache diary result (−158.79 vs. −38.63; P = .003), headache impact test-6 (HIT-6) score (−20.09 vs. −2.83; P < .001), and migraine headache index score (MHIS, −65.32 vs. −0.33; P < .001).
Study details: This was a randomized, double-blind trial including 92 female patients aged 20-50 years with episodic migraine who were randomly assigned to receive ALA (n = 47) or placebo (n = 45) for 3 months.
Disclosures: The study received financial support from the Isfahan University of Medical Sciences, Isfahan, Iran. The authors reported no potential conflict of interests.
Source: Kelishadi MR et al. Sci Rep. 2022;12:271 (Jan 7). Doi: 10.1038/s41598-021-04397-z.
Key clinical point: Alpha-lipoic acid (ALA) supplementation may serve as a potential adjunct treatment option for migraine.
Main finding: ALA supplementation vs. placebo over 3 months caused a significant decrease in baseline mean headache severity (−3.59 vs. −0.70; P < .001), frequency of attacks/month (−2.55 vs. −0.40; P = .001), headache diary result (−158.79 vs. −38.63; P = .003), headache impact test-6 (HIT-6) score (−20.09 vs. −2.83; P < .001), and migraine headache index score (MHIS, −65.32 vs. −0.33; P < .001).
Study details: This was a randomized, double-blind trial including 92 female patients aged 20-50 years with episodic migraine who were randomly assigned to receive ALA (n = 47) or placebo (n = 45) for 3 months.
Disclosures: The study received financial support from the Isfahan University of Medical Sciences, Isfahan, Iran. The authors reported no potential conflict of interests.
Source: Kelishadi MR et al. Sci Rep. 2022;12:271 (Jan 7). Doi: 10.1038/s41598-021-04397-z.
Key clinical point: Alpha-lipoic acid (ALA) supplementation may serve as a potential adjunct treatment option for migraine.
Main finding: ALA supplementation vs. placebo over 3 months caused a significant decrease in baseline mean headache severity (−3.59 vs. −0.70; P < .001), frequency of attacks/month (−2.55 vs. −0.40; P = .001), headache diary result (−158.79 vs. −38.63; P = .003), headache impact test-6 (HIT-6) score (−20.09 vs. −2.83; P < .001), and migraine headache index score (MHIS, −65.32 vs. −0.33; P < .001).
Study details: This was a randomized, double-blind trial including 92 female patients aged 20-50 years with episodic migraine who were randomly assigned to receive ALA (n = 47) or placebo (n = 45) for 3 months.
Disclosures: The study received financial support from the Isfahan University of Medical Sciences, Isfahan, Iran. The authors reported no potential conflict of interests.
Source: Kelishadi MR et al. Sci Rep. 2022;12:271 (Jan 7). Doi: 10.1038/s41598-021-04397-z.